KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference
Rhea-AI Summary
KALA BIO (NASDAQ:KALA) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference in New York. Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer, will deliver a presentation on December 4, 2024, at 11:30 a.m. ET. The company, which focuses on developing innovative therapies for rare and severe eye diseases, will also be available for one-on-one meetings during the conference. A webcast of the presentation will be accessible through the 'Presentations' section on KALA's website.
Positive
- None.
Negative
- None.
News Market Reaction – KALA
In the trading session that priced this news, KALA gained 2.49%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ARLINGTON, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer of KALA BIO, will present at the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY on Wednesday, December 4, 2024 at 11:30 a.m. ET. Management will also be available for one-on-one meetings on Wednesday, December 4, 2024.
To access the webcast and subsequent archived recording of the presentation, please visit the “Presentations” section of the KALA website at www.kalarx.com.
About KALA BIO, Inc.
KALA is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye. KALA’s biologics-based investigational therapies utilize KALA’s proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. KALA is also targeting the potential development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision and has initiated preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on KALA, please visit www.kalarx.com.
Investor Contact:
Taylor Steiner
taylor.steiner@precisionaq.com
212-362-1200
